Aptorum Group and DiamiR Biosciences Announce Merger to Enhance Diagnostics Capabilities

Aptorum Group ( (APM) ) just unveiled an update.

On July 14, 2025, Aptorum Group Limited and DiamiR Biosciences Corp. entered into a definitive merger agreement, whereby DiamiR will become a wholly-owned subsidiary of Aptorum. This merger aims to leverage DiamiR’s expertise in brain health diagnostics to enhance Aptorum’s capabilities in addressing unmet medical needs. The merger will result in DiamiR shareholders owning approximately 70% of the combined company, with Aptorum shareholders retaining 30%. The merger is expected to position the combined entity as a leader in non-invasive, blood-based testing, with a strong focus on brain health, potentially delivering significant value to shareholders.

Spark’s Take on APM Stock

According to Spark, TipRanks’ AI Analyst, APM is a Neutral.

Aptorum Group’s overall stock score of 41 reflects significant financial difficulties, with declining revenues and persistent losses as primary concerns. Technical analysis indicates bearish trends, and valuation metrics suggest the stock may be overvalued. The lack of earnings call and corporate events data leaves these areas unassessed.

To see Spark’s full report on APM stock, click here.

More about Aptorum Group

Aptorum Group Limited is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic assets to address unmet medical needs, particularly in oncology and infectious diseases. DiamiR Biosciences is a molecular diagnostics company specializing in minimally invasive tests for early detection and monitoring of neurodegenerative diseases and other health conditions, utilizing a proprietary platform technology based on microRNA analysis.

Average Trading Volume: 3,374,038

Technical Sentiment Signal: Hold

Current Market Cap: $11.5M

Learn more about APM stock on TipRanks’ Stock Analysis page.